Jane B Trepel Selected Research

Estrogen Receptors

1/2016	The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
6/2013	Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jane B Trepel Research Topics

Disease

69	Neoplasms (Cancer) 01/2024 - 01/2002
17	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 03/2003
12	Carcinoma (Carcinomatosis) 03/2024 - 03/2003
12	Breast Neoplasms (Breast Cancer) 10/2023 - 01/2002
9	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2021 - 01/2016
7	Disease Progression 01/2022 - 02/2014
6	Ovarian Neoplasms (Ovarian Cancer) 03/2024 - 01/2015
5	Lung Neoplasms (Lung Cancer) 07/2021 - 03/2005
4	Adenocarcinoma 01/2024 - 03/2005
4	Triple Negative Breast Neoplasms 10/2023 - 01/2018
4	Leukemia 11/2021 - 09/2002
4	Circulating Neoplastic Cells 01/2021 - 04/2016
4	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2007
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2021 - 08/2002
3	Neutropenia 12/2020 - 11/2014
3	Diarrhea 12/2020 - 11/2011
3	Urinary Bladder Neoplasms (Bladder Cancer) 05/2017 - 11/2015
3	Lymphoma (Lymphomas) 01/2017 - 06/2005
3	Carcinogenesis 08/2015 - 03/2003
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 09/2008
2	Nausea 12/2020 - 11/2014
2	Fatigue 12/2020 - 10/2005
2	Thrombocytopenia (Thrombopenia) 12/2020 - 11/2014
2	Glioma (Gliomas) 01/2020 - 01/2004
2	Renal Cell Carcinoma (Grawitz Tumor) 12/2019 - 04/2013
2	Thymoma (Thymic Carcinoma) 02/2015 - 02/2014
2	Pheochromocytoma 04/2013 - 01/2013
2	Hematologic Neoplasms (Hematological Malignancy) 05/2008 - 08/2002
2	Myeloid Leukemia (Leukemia, Myelocytic) 04/2007 - 08/2002
1	Cystadenocarcinoma 01/2024

Drug/Important Bio-Agent (IBA)

18	Histone Deacetylase InhibitorsIBA 01/2023 - 01/2004
15	Proteins (Proteins, Gene)FDA Link 07/2021 - 01/2005
14	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2015
14	entinostat (MS 275)IBA 01/2023 - 02/2002
12	PlatinumIBA 03/2024 - 01/2015
8	Immune Checkpoint InhibitorsIBA 01/2022 - 11/2015
7	Phosphotransferases (Kinase)IBA 12/2020 - 05/2008
6	AntigensIBA 07/2021 - 01/2005
6	RRx-001IBA 02/2021 - 01/2016
6	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2017 - 07/2011
5	Androgen Receptors (Androgen Receptor)IBA 01/2018 - 07/2011
5	STA 9090IBA 01/2017 - 12/2010
4	prexasertibIBA 03/2024 - 01/2018
4	exemestane (Aromasin)FDA Link 01/2023 - 06/2013
4	cabozantinibIBA 01/2022 - 01/2020
4	Messenger RNA (mRNA)IBA 01/2020 - 06/2004
4	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 11/2014
4	belinostatIBA 01/2018 - 11/2014
4	Molecular Chaperones (Chaperone, Molecular)IBA 02/2016 - 06/2013
3	Immunotoxins (Immunotoxin)IBA 01/2024 - 01/2020
3	Hormones (Hormone)IBA 10/2023 - 10/2021
3	EnzymesIBA 12/2021 - 12/2019
3	Aromatase InhibitorsIBA 10/2021 - 06/2013
3	VaccinesIBA 07/2021 - 08/2016
3	Docetaxel (Taxotere)FDA Link 01/2021 - 04/2010
3	B7-H1 AntigenIBA 01/2021 - 11/2015
3	Prednisone (Sone)FDA LinkGeneric 01/2021 - 04/2010
3	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 12/2020 - 08/2015
3	Peptides (Polypeptides)IBA 11/2019 - 08/2016
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019 - 07/2015
3	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 04/2016
3	olaparibIBA 01/2019 - 01/2015
3	romidepsin (FK228)FDA Link 01/2018 - 03/2005
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 02/2002
3	AndrogensIBA 01/2017 - 10/2005
3	DepsipeptidesIBA 09/2008 - 03/2004
3	beta CateninIBA 05/2008 - 08/2002
2	AntibodiesIBA 01/2024 - 12/2018
2	MesothelinIBA 01/2024 - 01/2020
2	LMB-100IBA 01/2024 - 01/2020
2	LigandsIBA 10/2023 - 01/2018
2	NivolumabIBA 01/2022 - 11/2020
2	Lenalidomide (CC 5013)FDA Link 11/2021 - 10/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2021 - 11/2014
2	Lactic Acid (Lactate)FDA LinkGeneric 11/2020 - 01/2020
2	InterferonsIBA 01/2020 - 05/2009
2	cediranib (AZD2171)IBA 01/2019 - 01/2015
2	Protein Isoforms (Isoforms)IBA 01/2019 - 06/2013
2	durvalumabIBA 01/2019 - 12/2018
2	Oncogene Proteins (Oncogene Protein)IBA 12/2018 - 10/2012
2	TARPIBA 12/2018 - 08/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 03/2005
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2018 - 01/2018
2	Androgen Antagonists (Antiandrogens)IBA 01/2018 - 11/2013
2	EndoglinIBA 01/2017 - 10/2015
2	carotuximabIBA 01/2017 - 10/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 01/2002
2	Bevacizumab (Avastin)FDA Link 10/2016 - 04/2010
2	Estrogen ReceptorsIBA 01/2016 - 06/2013
2	Tyrosine (L-Tyrosine)FDA Link 08/2015 - 05/2008
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2014 - 12/2004
2	tanespimycin (17AAG)IBA 01/2013 - 12/2010
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 06/2004 - 01/2002
1	tofacitinibIBA 01/2024
1	ExotoxinsIBA 01/2024

Therapy/Procedure

27	Therapeutics 11/2023 - 03/2003
7	Immunotherapy 11/2021 - 11/2015
7	Drug Therapy (Chemotherapy) 02/2021 - 02/2015
7	Castration 01/2021 - 04/2010
2	Aftercare (After-Treatment) 01/2020 - 12/2018